---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036346"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T17:24:53.850151+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Windtree reports Q3 net loss $3.8M; cash runway only through Jan 2025

## Summary
- Operating loss $4.7M flat vs Q3 2023; net loss $3.8M ($4.23/share) vs $4.4M ($15.47/share) a year ago.
- Cash $2.3M at Sep 30; subsequent ELOC sales raised $2.4M net; funds only through January 2025.
- Positive Phase 2b istaroxime data in early cardiogenic shock: primary SBP AUC endpoint met; safety favorable.
- July 2024 private placements raised ~$13.9M aggregate ($4.4M new cash, $9.5M debt conversion); $35M ELOC secured.
- Nasdaq non-compliance for late 10-Q resolved after filing on Nov 26; listing compliance restored Nov 27.

## SEC filing metadata
- accession: 0001437749-24-036346
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924036346/0001437749-24-036346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924036346/wint20240909_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036346
- JSON: https://secwatch.observer/filing/0001437749-24-036346.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.